ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,571,857 | -15.6% | 3,705,669 | -4.4% | 0.26% | -7.2% |
| Q2 2023 | $119,122,203 | -16.9% | 3,875,153 | -2.6% | 0.28% | -22.8% |
| Q1 2023 | $143,342,293 | +3.1% | 3,978,415 | +13.1% | 0.36% | -5.0% |
| Q4 2022 | $139,010,692 | +0.7% | 3,517,477 | +2.4% | 0.38% | -8.0% |
| Q3 2022 | $137,981,000 | -8.0% | 3,434,072 | -3.7% | 0.41% | -12.7% |
| Q2 2022 | $149,952,000 | +71.5% | 3,566,894 | +59.3% | 0.47% | +110.3% |
| Q1 2022 | $87,450,000 | -4.0% | 2,239,130 | -2.0% | 0.22% | +12.0% |
| Q4 2021 | $91,093,000 | +39.9% | 2,285,899 | +26.9% | 0.20% | +36.1% |
| Q3 2021 | $65,094,000 | -15.7% | 1,801,145 | -4.4% | 0.15% | -13.0% |
| Q2 2021 | $77,235,000 | +6088.7% | 1,884,011 | +6482.2% | 0.17% | +5533.3% |
| Q1 2021 | $1,248,000 | +144.7% | 28,623 | +180.5% | 0.00% | +200.0% |
| Q4 2020 | $510,000 | – | 10,203 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |